PAPA Syndrome: Challenges in Achieving Long-Term Remission

Area of Science:

• Genetics and Immunology
• Dermatology
• Rheumatology

Background:

• PAPA syndrome is an autoinflammatory disorder caused by PSTPIP1 gene mutations, leading to abnormal inflammasome activation and elevated pro-inflammatory cytokines like IL-1β and TNF-α.
• Current treatments include corticosteroids and biologics targeting TNF-α or IL-1, but data is scarce, and treatment responses are inconsistent.

Observation:

• A 22-year-old male with PAPA syndrome, confirmed by E250Q PSTPIP1 mutation, presented with severe acne and pyoderma gangrenosum-like ulcers, while joint symptoms were milder.
• The patient had a history of unspecific joint disease, severe acne, persistent ulcers, and a pathergy phenomenon, with prior treatments including NSAIDs, corticosteroids, methotrexate, TNF-α, and IL-1 inhibitors with varying success.

Findings:

• A 12-month multi-agent regimen of adalimumab, isotretinoin, and a short course of prednisone stabilized the patient's condition, alleviating acute skin changes and slowing symptom exacerbation.
• Adalimumab showed efficacy for cutaneous manifestations, while isotretinoin targeted acne. Corticosteroids provided initial relief but were limited by side effects.
• Treatment discontinuation led to symptom exacerbation, highlighting the need for sustained therapeutic strategies and further research.

Implications:

• This case underscores the diagnostic delay and treatment challenges in PAPA syndrome, emphasizing the potential of multi-agent therapy for managing complex manifestations.
• The findings highlight the need for more robust clinical trials to establish evidence-based guidelines for PAPA syndrome treatment, aiming for long-term remission and improved quality of life.
• Further research into the complex immunological pathways involved in PAPA syndrome is crucial for developing more effective and targeted therapies.